Introduction
The Haemophilus influenzae type b (Hib) vaccine has not been introduced in Japan, and in this country H. influenzae remains a major cause of meningitis in children aged ‡3 months. 1 Surveillance indicates that the incidence of Hib meningitis in Japan is 10/100 000 in children under 5 years. This is in marked contrast to the low rates in countries where the Hib vaccine has been introduced. 2 In the past 6 years, b-lactam-resistant strains of Streptococcus pneumoniae and Hib isolates from patients with meningitis have been rapidly increasing in parallel with their increase in patients with respiratory tract infections (RTIs) in Japan. 1, [3] [4] [5] Of these pathogens, b-lactamase-non-producing ampicillin-resistant (BLNAR) Hib isolates have exponentially increased from 5.8% in 2000 to 34.5% in 2004. Although H. influenzae strains showing decreased affinities for b-lactams were first described in the USA in the 1980s, 6 ,7 these strains are rare in the USA and also in the EU. 8, 9 The ampicillin resistance mechanism in BLNAR strains results from mutations in the ftsI gene encoding penicillin-binding protein 3 (PBP3), which mediates septal peptidoglycan synthesis in the cell wall. We have identified three mutations associated with decreased susceptibility to b-lactams. 10 BLNAR strains have the amino acid substitutions N526K or R517H and S385T, while strains with the amino acid substitution N526K or R517H alone, and which have slightly lower ampicillin MICs than BLNAR strains, are designated low-BLNAR (Table 1) .
In this paper, we describe the results obtained by the Nationwide Surveillance Study Group for Bacterial Meningitis (NSBM) Working Group for Hib isolates in meningitis, with regard to yearly changes in genotypic resistance and verification of the correlation between antibiotic susceptibility and diversity of the ftsI gene.
Materials and methods

Strains
A total of 621 H. influenzae isolates were collected from clinical laboratories at 285 Japanese medical institutions participating in the NSBM Working Group between January 2000 and December 2004. These institutions were recruited on the basis of their proximity to major metropolitan areas. PCR was immediately performed on all isolates as described below to determine the ftsI mutations, after which production of b-lactamase was confirmed by a nitrocefin test (Showa Chemical Inc., Tokyo, Japan). Isolates were all stored at -80 C for subsequent testing. The samples were collected after obtaining informed consent from family members in the case of infants and children.
PCR
PCR was carried out using six sets of primers reported previously: 8, 11 the six targets included the 16S rRNA gene (for identification of H. influenzae), part of the TEM b-lactamase gene, 12 part of the ROB b-lactamase gene, 13 an N526K amino acid substitution in the ftsI gene, an S385T amino acid substitution in the ftsI gene and a portion of the Hib-specific capB locus.
14 PCR cycling conditions were 35 cycles at 94 C for 15 s, at 53 C for 15 s and at 72 C for 15 s. Isolates suspected of having an R517H substitution on the basis of their susceptibility to ampicillin and cefotaxime were subjected to direct sequencing to detect this substitution because useful primers could not be designed. 8 
Antibiotic susceptibility
Isolates were tested for susceptibility to ampicillin (Meiji Seika Kaisha, Tokyo, Japan), cefotaxime (Aventis Pharma Ltd, Tokyo, Japan), ceftriaxone (Chugai Pharmaceutical Co., Ltd, Tokyo, Japan) and meropenem (Dainippon Sumitomo Pharma Co., Ltd, Osaka, Japan) using an agar dilution method. 15 
Sequencing
The 1.0 kb DNA fragment of the ftsI gene encoding the PBP3 transpeptidase domain was amplified from the chromosomal DNA of all BLNAR and TEM-1 b-lactamase-producing amoxicillin/ clavulanic acid-resistant (BLPACR) strains identified by the PCR method described above and was sequenced by the method reported previously. 10 
Transformation
An open reading frame that corresponded to the ftsI gene was amplified and transformed into the Rd strain (ATCC 51907) as described previously 10 in a cuvette with a 0.1 cm electrode gap using a MicroPulser TM electroporation apparatus (Bio-Rad Laboratories, Hercules, CA, USA). The conditions for electroporation were 1.8 kV/cm with time constants of 5.8-5.9 ms. Colonies grown on selective agar plates containing cefotaxime at 0.031 and 0.063 mg/L were selected at random, and the MICs of the b-lactam antibiotics for the colonies were determined. The ftsI gene was also sequenced for several transformants to confirm gene transfer.
Results
Age distribution of cases
Among isolates from 621 cases of meningitis, 617 (99.4%) were type b and 4 were non-typeable. The prevalence of H. influenzae BLNAS, b-lactamase-non-producing ampicillin-susceptible H. influenzae; BLPAR, b-lactamase-producing ampicillin-resistant H. influenzae; low-BLNAR, b-lactamase-non-producing low-level ampicillin-resistant H. influenzae; BLNAR, b-lactamase-non-producing ampicillin-resistant H. influenzae; BLPACR, b-lactamase-producing amoxicillin/clavulanic acidresistant H. influenzae.
meningitis peaked in patients who were 1 year of age (n = 167, 26.9%), and was next highest in patients aged between 7 and 11 months (n = 120, 19.3%), and then in patients who were 1-6 months aged (n = 106, 17.1%). The total number of isolates from patients aged between 1 and 11 months (n = 226, 36.4%) was higher than that in patients who were 1 year of age. Hib meningitis gradually became less prevalent after the age of 2 years and was rare by the age of 5 years. b-Lactam-resistant strains including BLNAR strains were isolated at the same rate in all age groups. Table 1 shows the correlation between resistance genes and susceptibility to the four b-lactams used for empirical treatment of meningitis. The isolates could be grouped into the following six classes: b-lactamase-non-producing ampicillin-susceptible (BLNAS) (n = 155; 25.0%); TEM-1 b-lactamase-producing ampicillin-resistant (BLPAR) (n = 68; 11.0%); low-BLNAR (n = 189; 30.4%), BLNAR (n = 138; 22.2%); BLPACR-I with either a N526K or R517H substitution in the ftsI gene (n = 59; 9.5%) and BLPACR-II with an S385T substitution together with either a N526K or R517H substitution in the ftsI gene (n = 12; 1.9%). No ROB-1-positive strains were detected. The MIC 50 s of ampicillin were 1 mg/L for low-BLNAR and 2 mg/L for BLNAR, four to eight times higher than the value of 0.25 mg/L for BLNAS. In contrast, the MIC 50 s of cefotaxime and ceftriaxone for the resistant strains were clearly increased. MIC 50 of cefotaxime was 0.063 mg/L for low-BLNAR and 0.5 mg/L for BLNAR, 32 times higher than the value of 0.016 mg/L for BLNAS. Similarly, the MIC 50 of ceftriaxone for BLNAR was 0.125 mg/L, 32 times higher than the value of 0.004 mg/L for BLNAS.
Susceptibility of H. influenzae to intravenous agents
The MICs of meropenem for the resistant strains were affected a little by the ftsI gene mutations. The MIC 50 of meropenem for low-BLNAR and BLNAR was 0.125 mg/L, four times higher than the value of 0.031 mg/L for BLNAS. Table 2 shows the yearly changes in resistance types classified genotypically among the strains between 2000 and 2004. BLNAR strains were not isolated during half a year in 1999, though the prevalences of low-BLNAR and BLPAR were 29.2% and 31.7%, respectively. However, BLNAR strains were isolated in 2000, since when their prevalence has increased, accounting for 34.5% of isolates in 2004. In contrast, the incidence of BLNAS and BLPAR strains gradually decreased to 22.4% and 7.8%, respectively, in 2004. The incidence rates of low-BLNAR, BLPACR-I and BLPACR-II strains were broadly flat during the 5 years.
Yearly changes of resistance
Amino acid substitution in the ftsI gene Table 3 shows the amino acid substitutions in the ftsI genes in BLNAR (n = 138) and BLPACR-II (n = 12) strains classified into nine subgroups on the basis of variation of substitution patterns. BLNAS strain MT196 was taken as the standard ampicillinsusceptible strain. In the BLNAR strains, the six amino acid substitutions shown in Table 3 were important for the development of resistance. Of these substitutions, N526K and R517H were the substitutions which are the base of phenotypic resistance, and three amino acid substitutions were identified surrounding the conserved SSN motif. S385T was common to the II-IV and VI-IX subgroups, and M377I and L389F substitutions were also identified. Strains in subgroup IX with these three substitutions surrounding the SSN motif were the most prevalent.
With regard to the correlation of the number of substitutions and antibiotic susceptibility, the MIC 50 of ampicillin for the BLNAR with three substitutions of S385T, M377I and L389F was only either two or four times higher than those for the low-BLNAR strains. However, the MIC 50 s of cefotaxime and ceftriaxone for BLNAR were clearly increased by the additional amino acid substitutions.
Transformation
Ampicillin-susceptible strain Rd was transformed with PCRamplified ftsI genes from isolates of each of the nine subgroups of BLNAR strains. The transformation frequency was 1-3/10 7 . As shown in Figure 1 , the MICs of cefotaxime for each transformant increased with additional substitutions in the ftsI gene. The cefotaxime MICs for transformants were as follows: N526K, 0.063 mg/L; S385T + N526K, 0.25 mg/L; M377I + S385T + L389F + N526K, 0.5 mg/L. The cefotaxime MICs for transformants with the four amino acid substitutions of subgroup IX were 64 times higher than the value of 0.008 mg/L for the parent Rd strain. The ampicillin MIC (1 mg/L) for transformants of subgroup IX was only four times higher than the value of 0.25 mg/L for the parent strain Rd. The meropenem MIC for transformants of subgroup IX was 0.063 mg/L, the same as that for the parent Rd strain. The correlations between mutation in the ftsI gene and susceptibility to ampicillin and meropenem were poor. 
Increase of causative BLNAR in meningitis Discussion
Low-BLNAR strains of H. influenzae were first described in the USA in the 1980s, 6,7 but were not considered an important clinical problem. Instead, TEM-1-and ROB-1-type BLPAR strains have been prevalent to 26% and 10%, respectively, in the USA in 1999, 8 and, accordingly, amoxicillin/clavulanic acid has been recommended as a first-line oral antibiotic therapy. [16] [17] [18] On the other hand, in Japan, TEM-1-type BLPAR appeared in the 1980s and had a prevalence of 15-20% until 1995, after which its prevalence gradually declined to 3% in 1999. 8 The reason for the decrease in prevalence was the development and predominant use of oral third-generation cephalosporin antibiotics which are stable with respect to b-lactamase.
According to retrospective analysis of the ftsI gene in H. influenzae, low-BLNARs with amino acid substitution The antimicrobial activity of cephalosporins against H. influenzae is due to their high affinity for PBP3. Thus, under the selective pressure imposed by oral cephalosporin usage, strains with mutations in the ftsI gene which reduce the binding affinity of PBP3 are selected.
As shown in Table 3 , of the nine subgroups identified among the BLNAR and BLPACR-II isolates of H. influenzae, resistant strains belonging to subgroup IX with three amino acid substitutions surrounding the SSN motif and N526K in the ftsI gene were predominantly isolated. These strains in particular showed decreased susceptibility to intravenous cephalosporins, such as cefotaxime and ceftriaxone, which are used for meningitis patients. The results of transformation experiments also supported the fact that the wide distribution of the b-lactam MIC for Hib-type BLNARs reflects the variety of ftsI mutations. These results point to the possible emergence of more highly resistant Hib-type BLNARs possessing new amino acid substitutions in the future.
For clinical efficacy in the treatment of meningitis, it is thought that the concentration of cephalosporins in the CSF needs to be 10-20 times greater than the MIC for the infection strain. At the present time, combination chemotherapy has shifted from ampicillin and cefotaxime to cefotaxime and meropenem or ceftriaxone and meropenem for meningitis patients with BLNAR in Japan. The peak concentrations in CSF achieved following intravenous administration range from 2.6-13.2 mg/L for cefotaxime (at a dosage of 50 mg/kg every 6 h), 7.7 mg/L for ceftriaxone (50 mg/kg every 12 h) and 0.3-2.8 mg/L for meropenem (40 mg/kg every 8 h).
19, 20 The CSF levels of these agents ranged from 5-26 times the MIC 50 of cefotaxime for BLNAR, 62 times the MIC 50 of ceftriaxone and 3-22 times the MIC 50 of meropenem. Monotherapy with these agents for meningitis caused by BLNAR is suspected to be insufficient clinically in some cases.
Data were not shown here, but some meningitis patients have failed monotherapy with cefotaxime or ceftriaxone, and combination therapy was required with b-lactams having different target for PBP, such as cefotaxime and meropenem or ceftriaxone and meropenem. A questionnaire survey of patients with meningitis indicated that the incidence of severe sequelae was 19.6% (K. Hasegawa, R. Kobayashi, E. Takada, A. Ono, N. Chiba, M. Morozumi, S. Iwata, K. Sunakawa and K. Ubukata, unpublished results). The details will be described in another paper.
Furthermore, according to the NSBM study over 6 years, cases of meningitis caused by BLNAR strains have increased, with the prevalence of these strains being particularly high in patients £1 year of age who were immuno immature. An increase in the number of the day nursery children seems to accelerate the increase of infectious diseases caused by these resistant strains. Government approval of the introduction of Hib vaccine should prevent severe Hib infections, including those caused by BLNAR and BLPACR-II strains.
